Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer (Q38932418)

7 September 2017

Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer (English)

1 reference

7 September 2017

1 reference

1 reference

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

20

Hiroyuki Yamamoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

21

Katsuhiko Nosho

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

18

Kohzoh Imai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

22

Yasuhisa Shinomura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1

Hisayoshi Igarashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

12

Yasutaka Sukawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

Miki Ito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

3

Kei Mitsuhashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2

Hiroyoshi Kurihara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

6

Shinichi Kanno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

7

Takafumi Naito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

8

Shinji Yoshii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

19

Hiromu Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

17

Yoshifumi Baba

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

5

Hiroyuki Okuda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

10

Takaya Kusumi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

14

Kenji Okita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Hiroaki Takahashi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Tadashi Hasegawa

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Koichi Hirata

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yu Imamura

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

4 December 2014

1 reference

Annals of Surgical Oncology

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

2640-2648

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472647%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1245/s10434-014-4264-7

10 June 2020

exact match

0 references

cites work

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Colorectal cancers with microsatellite instability display unique miRNA profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Role of miR-143 targeting KRAS in colorectal tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

NRAS mutations are rare in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4264-7